Dr Thomas Duthy, Executive Director of Neurotech said “We thank the Monash HREC for this extension,
which provides comfort to our Phase I/II trial participants that they are able to receive NTI164 therapy
for an additional 52 weeks above existing approvals. We continue to focus our resources on
completing the current Phase II/III ASD trial and remain on track to report the results of our Phase II/III
ASD trial in late Q1 CY2024 to early Q2 CY2024.”
Ann: Neurotech Receives Additional HREC Approval in Autism, page-2
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.4¢ |
Change
-0.002(2.63%) |
Mkt cap ! $75.28M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.4¢ | $309.2K | 4.073M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45202 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.31pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
-0.002 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.7¢ | 7.4¢ | 135838 | ||
| Last updated 15.09pm 24/05/2024 ? | |||||
| NTI (ASX) Chart |